AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00169897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (teaching and exercise)
Description: After a 4-week education program, patients took part to home-based rehabilitation or outpatient hospital-based rehabilitation for 8 weeks. Patients were subsequently followed for 40 weeks to complete the one-year study.
Study NCT01248546 — intervention group
Intervention type: PROCEDURE
Intervention: Digital breast tomosynthesis
Description: The participants included in the trial will have an additional radiation exposure for breast tomosynthesis
Study NCT01372098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NFP + IPV intervention
Description: The intervention focuses on helping women stay safe in a relationship. Strategies for overcoming barriers to using and accessing community resources and services, and community agency interventions for women exposed to IPV is built into the intervention.
Study NCT04017676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervision assissted by measures
Description: In the weeks 10 and 13, about 72 hours after the meeting scheduled for that week, and before the next therapeutic session, there will be a structured training session (based on the recommendations of Krägeloh et al., 2015), based on information in the literature about the various questionnaires
Study NCT00352911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VGX-410 (Mifepristone)
Study NCT00352911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for VGX-410 (Mifepristone)
Study NCT01295177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: topic cream insulin
Description: Intervention: Placebo cream versus insulin cream. Patients with wounds for more than 3 months without infection. These patients were treated with placebo cream or insulin cream. The placebo or insulin were used for 8 weeks.
Study NCT01173406 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPAP education
Description: Standard CPAP education plus an session and one telephone follow up
Study NCT01173406 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: CPAP education
Description: Standard CPAP education plus an session and one telephone follow up
Study NCT04375020 — intervention group
Intervention type: DRUG
Intervention: GABA
Description: GABA nutritional supplement 750mg per day for 6 months
Study NCT03995667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03995667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields Therapy
Description: Optune-Tumor Treating Fields (TTFields). Transducer arrays affixed to scalp, worn continuously.
Study NCT03364712 — intervention group
Intervention type: OTHER
Intervention: routine medical care, venipuncture
Study NCT04538456 — intervention group
Intervention type: OTHER
Intervention: questionnaire and optional interview
Description: Participants will be sent an online or paper questionnaire. If participants have expressed an interest in taking part in an interview, they may be contacted by a member of the research team. The interviews will be conducted over the phone at time suitable for the participant. There will be no study specific hospital visits.
Study NCT03736473 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MEDI9447 (oleclumab)
Description: MEDI9447 administered intravenously
Study NCT02949804 — intervention group
Intervention type: BEHAVIORAL
Intervention: Comparison between two groups
Description: Comparison will be made between smokers and non smokers regarding vasovagal tendency
Study NCT02950064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTP-114
Description: Part 1 (Escalation) IV treatment of BTP-114 in 21-day cycles. Doses will be increased in sequential cohorts until the maximum tolerated dose is determined which will lead to the recommended phase 2 dose~Part 2 (Expansion) 5 cohorts of patients will be treated at the RP2D of IV BTP-114 in 21-day cycles for the tumor types pancreatic cancer, castration-resistant prostate cancer, ovarian cancer, triple-negative breast cancer and deoxyribonucleic acid (DNA) repair mutation-positive advanced solid tumors.
Study NCT03723876 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body awareness therapy
Description: The physiotherapist uses body awareness techniques, i.e. guiding the participant in movement qualities such as stability, breathing, flow and grounding. Conscious awareness focused on bodily experiences is a key component to be able to reflect on what your body signals.~As a baseline a standardized observation of the movement quality of the individual is performed. The physiotherapist needs special education in the body awareness technique used, to rightly perform and analyse the observation and administer the intervention.~The aim of the body awareness therapy is to raise physical and mental awareness by strengthening the interplay between sensory impressions and motor ability and to gain knowledge of own movement patterns that are not functional and to form alternatives to these.
Study NCT02910739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-8931
Description: MK-8931 40 mg
Study NCT02910739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8931
Description: MK-8931 40 mg
Study NCT02391779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BeneFlax®
Description: Daily ingestion of 600 mg SDG/day in 1.6 g SDG-enhanced flax lignan (BeneFlax®) with walking training or flexibility training
Study NCT02391779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking training
Description: 30-60 minutes walking training, 5 days/week.
Study NCT02391779 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Walking training
Description: 30-60 minutes walking training, 5 days/week.
Study NCT02391779 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Walking training
Description: 30-60 minutes walking training, 5 days/week.
Study NCT02391779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flexibility training
Description: 5 days/week; e.g. stretching training at home
Study NCT02391779 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Flexibility training
Description: 5 days/week; e.g. stretching training at home
Study NCT02391779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Whey Protein)
Description: 0.6 g/day (an amount equal in volume to BeneFlax®) with walking training or flexibility training
Study NCT02391779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dash Eating Plan
Description: Dietary Approaches to Stop Hypertension (DASH), a balanced eating plan - all participants in all treatment arms will be encouraged to adopt a DASH eating plan.
Study NCT02581813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I.D.E.A.L. for Adolescents Study - Higher Dairy
Description: 12 weeks diet and exercise intervention characterized by higher dairy consumption (4 servings per day) and exercise 3 times per week
Study NCT02581813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I.D.E.A.L. for Adolescents Study - Lower Dairy
Description: 12 weeks diet and exercise intervention characterized by lower dairy consumption (0-1 serving per day) and exercise 3 times per week
Study NCT00124943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoparticle Paclitaxel
Description: Nanoparticle albumin-bound paclitaxel, administered via intracoronary catheter.
Study NCT03063177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy
Description: A SMT will be delivered by contacting the transverse processes of T7 through our apparatus. Each participant will receive one SMT per session for 3 sessions.
Study NCT01181063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 320/9 μg and 400/12 μg inhalers
Description: Budesonide/formoterol 320/9 μg and 400/12 μg in different kind of inhalers and Symbicort Turbuhaler forte 320/9 μg. Ech subject will be randomly allocation to 4 of 5 products, a single dose administration of each product
Study NCT01181063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/formoterol 320/9 μg and 400/12 μg inhalers
Description: Budesonide/formoterol 320/9 μg and 400/12 μg in different kind of inhalers and Symbicort Turbuhaler forte 320/9 μg. Ech subject will be randomly allocation to 4 of 5 products, a single dose administration of each product
Study NCT01222689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT01222689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Given PO
Study NCT01222689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03642587 — intervention group
Intervention type: OTHER
Intervention: There is no intervention in this study.
Description: There is no intervention in this study.
Study NCT03980080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSE-127
Description: mAb antagonist to CD127 receptor (or IL-7Rα)~Group 1-7~6 escalating dose level groups IV~SC
Study NCT03980080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle study drug
Study NCT02391779 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Dash Eating Plan
Description: Dietary Approaches to Stop Hypertension (DASH), a balanced eating plan - all participants in all treatment arms will be encouraged to adopt a DASH eating plan.
Study NCT02391779 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dash Eating Plan
Description: Dietary Approaches to Stop Hypertension (DASH), a balanced eating plan - all participants in all treatment arms will be encouraged to adopt a DASH eating plan.
Study NCT02486744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acthar Gel
Description: Subjects will be given an injection subcutaneously 2x week for 6 months. Dosing will be randomly assigned as either 80 U or 40 U
Study NCT02941562 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: Preoperative Radiation doses: 25 Gy in 5 fractions to the pelvis
Study NCT02941562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4 chemotherapy,preoperative
Description: FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks
Study NCT02941562 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy of neo-adjuvant therapy
Description: Preoperative Radiation doses: 45 Gy in 25 fractions to the pelvis, 5.4 Gy in 3 fractions to the pelvis
Study NCT02941562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemotherapy of neo-adjuvant therapy
Description: Capecitabine 825mg/m2 twice daily 5 days/week
Study NCT02941562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical rectal cancer resection
Description: Radical rectal cancer resection
Study NCT02941562 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical rectal cancer resection
Description: Radical rectal cancer resection
Study NCT02941562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4 chemotherapy,post-operative
Description: FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks
Study NCT02941562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX4 chemotherapy,post-operative
Description: FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks
Study NCT03813420 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Description: The sleep quality was evaluated through the Turkish version of the PSQI containing 19 self-rated questions searching the sleep quality during the previous month. It has seven components as subjective sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction.~Each component is scored from 0 to 3, and the Global Pittsburgh Quality of Sleep (PQS) score is the sum of the scores of the seven components that is between 0 and 21. The higher Global PQS scores indicate poor sleep quality and the cut off score for poor sleep is 5 and over.
Study NCT03813420 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: International Physical Activity Questionnaire (IPAQ)
Description: The physical activity of the participants was assessed through the Turkish version of the International Physical Activity Questionnaire -Short Form (IPAQ-SF), which includes 6 questions searching the frequency (days per week) and duration (hours) of walking, as well as low, moderate and vigorous physical activity that they engaged in during the last seven days prior to survey. Vigorous physical activity, defined by the questionnaire, referred to intense exercise that resulted in very rapid breathing and an elevated heart rate (e.g. intense weight lifting, aerobics, running, and cycling). Moderate physical activity was defined as less intense exercise that slightly heightened breathing and heart rate (e.g. less exertive cycling, fast walking, and light weight lifting).
Study NCT03813420 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The Short Form 36 Health Survey (SF-36)
Description: The Turkish version of SF-36 was used to understand the health related quality-of -life (HRQOL) of the participants over the past four weeks in eight health concepts: limitations in physical activities because of health problems; limitations in social activities because of physical or emotional problems; limitations in usual role activities because of physical health problems; bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities because of emotional problems; vitality (energy and fatigue); and general health perceptions. Additionally, the psychometric evaluation of the SF-36 generated two summary scores as the Mental Health Component Score and the Physical Health Component Score that the higher scores indicate better HRQOL.
Study NCT03344653 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System
Description: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by 1 month DAPT
Study NCT03344653 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biosensors BioFreedom BA9 Drug Coated Coronary Stent
Description: Biosensors BioFreedom BA9 Drug Coated Coronary Stent Followed by 1 month DAPT
Study NCT02857166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: humanized anti-PD-1 monoclonal antibody toripalimab
Description: humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
Study NCT01340651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib was supplied as SR and IR formulated tablets.
Study NCT02513719 — intervention group
Intervention type: DEVICE
Intervention: XIENCE PRIME SV Everolimus Eluting Coronary Stent
Description: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent
Study NCT04421833 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: TOVERTAFEL
Description: The TOVERTAFEL is a small box that can be attached to the ceiling. Inside the box is a high-quality projector, infrared sensors, a speaker, and a processor that work together to project games onto the table. Because the colored objects respond to the movements of the hands and arms, the residents can play with the light itself.~The planned activities provide cognitive, social and physical stimulation through light projections and can all be used individually or in groups with the presence of a caregiver or facilitator. Sixteen play activities are offered.
Study NCT04421833 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TOVERTAFEL
Description: The TOVERTAFEL is a small box that can be attached to the ceiling. Inside the box is a high-quality projector, infrared sensors, a speaker, and a processor that work together to project games onto the table. Because the colored objects respond to the movements of the hands and arms, the residents can play with the light itself.~The planned activities provide cognitive, social and physical stimulation through light projections and can all be used individually or in groups with the presence of a caregiver or facilitator. Sixteen play activities are offered.
Study NCT04421833 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: USUAL activities
Description: patients can participate in cooking workshops, cinema activities (screening of old films or documentaries on a large screen, in a cozy atmosphere), walks in the garden and the visit of a dog trained in assisted therapy by the animal.
Study NCT04421833 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: USUAL activities
Description: patients can participate in cooking workshops, cinema activities (screening of old films or documentaries on a large screen, in a cozy atmosphere), walks in the garden and the visit of a dog trained in assisted therapy by the animal.
Study NCT02948023 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ex-vivo cultivated limbal stem cell pool
Description: 0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement.
Study NCT00617253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-21
Description: 3 mcg/kg, s.c. injection
Study NCT00617253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: Hard gelatine capsules, 12.5 mg
Study NCT00617253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-21
Description: 10 mcg/kg, s.c. injection
Study NCT00617253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-21
Description: 30 mcg/kg, s.c. injection
Study NCT00617253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-21
Description: 100 mcg/kg, s.c. injection
Study NCT04581954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: Ruxolitinib is a Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor approved for clinical use in the treatment of splenomegaly, myelofibrosis, polycythaemia vera and graft-versus-host disease. It is an oral agent with a rapid mode of action.
Study NCT04581954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fostamatinib
Description: Fostamatinib is a tyrosine kinase inhibitor with activity against spleen tyrosine kinase (SYK). It has approved for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Study NCT04581954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care treatment as per site-level policies and guidelines.
Study NCT02785471 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening for Mental Health only
Description: Participants in the Screening for Mental Health (SMH)-only group will complete the online depression and suicide screening and receive immediate feedback and referrals.
Study NCT02785471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening for Mental Health & Man Therapy
Description: Participants assigned to Screening for Mental Health, plus Man Therapy (SMH+MT) group will be offered the Man Therapy program in conjunction with Screening for Mental Health. MT provides online early intervention services designed specifically for men who are at risk for suicide and are less likely to engage in help-seeking behavior. MT takes an innovative and humorous approach to mental health education and help seeking through a fictional therapist named Dr. Rich Mahogany, who is a no-nonsense man's man who informs men about the importance of honest talk about life's challenges in addressing their problems. The web portal allows review manly mental health information, facts and tips, explore man therapies, and view videos of men with lived experience.
Study NCT03834038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyophilized Fecal Microbiota Transplantation
Description: Lyophilized FMT
Study NCT03045068 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Transfusion
Description: Post CPB- Platelet transfusion 20ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion.~1. Initial transfusion to occur proximal to the hemofilter on the MUF circuit for as long as MUF lasts~2. Subsequent platelet transfusion continued till completion via central venous access to the patient
Study NCT03045068 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Transfusion
Description: Post CPB- Platelet transfusion 20ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion.~1. Initial transfusion to occur proximal to the hemofilter on the MUF circuit for as long as MUF lasts~2. Subsequent platelet transfusion continued till completion via central venous access to the patient
Study NCT03045068 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FFP and Cryoprecipitate
Description: 1. 1 unit of cryoprecipitate administered during MUF and or after MUF as needed~2. FFP transfusion 10ml/kg during MUF and or after MUF as needed